Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410906 | 0.85 | S1PR1 (0.58) | S1PR1S1PR3S1PR5NPC1 | |
| SCHEMBL10247474 | 0.85 | S1PR1 (0.49) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL408170 | 0.84 | S1PR1 (0.55) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL558527 | 0.84 | S1PR1 (0.53) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL10246830 | 0.83 | S1PR1 (0.62) | S1PR1S1PR3S1PR5NPC1RAB9A | |
| SCHEMBL408845 | 0.82 | S1PR1 (0.58) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL10246755 | 0.81 | S1PR1 (0.51) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL10247215 | 0.81 | S1PR1 (0.47) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL409796 | 0.81 | S1PR1 (0.66) | S1PR1S1PR3S1PR5KDM4ENPC1 | |
| SCHEMBL10246926 | 0.79 | S1PR1 (0.55) | S1PR1S1PR3S1PR5KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | S1PR1 448/4885S1PR3 310/4885S1PR5 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.